Your browser doesn't support javascript.
loading
Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment.
Gu, Shenda; Ngamcherdtrakul, Worapol; Reda, Moataz; Hu, Zhi; Gray, Joe W; Yantasee, Wassana.
Afiliación
  • Gu S; Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, United States of America.
  • Ngamcherdtrakul W; Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, United States of America.
  • Reda M; PDX Pharmaceuticals, LLC, Portland, Oregon, United States of America.
  • Hu Z; Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, United States of America.
  • Gray JW; Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, United States of America.
  • Yantasee W; Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, United States of America.
PLoS One ; 13(6): e0198141, 2018.
Article en En | MEDLINE | ID: mdl-29879129

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Resistencia a Antineoplásicos / ARN Interferente Pequeño Límite: Female / Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Resistencia a Antineoplásicos / ARN Interferente Pequeño Límite: Female / Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos